Moderna stock extended its extraordinary rebound Tuesday after Wolfe Research upgraded MRNA to Peer Perform from Underperform following the Phase 3 success of its personalized cancer therapy intismeran autogene, developed with Merck. Wolfe now sees a substantially clearer path toward regulatory approval in melanoma and estimates $9.2 billion in unadjusted peak sales across four potential cancer indications, transforming the debate around Moderna from a shrinking COVID-vaccine company into a potentially major oncology platform.
The upgrade comes after one of the most dramatic biotech rallies in years. Moderna shares surged roughly 177% on August 19 after the Phase 3 announcement and have gained more than 120% over the past week, meaning investors are no longer buying the cancer story at distressed prices. The central question for MRNA stock has therefore shifted quickly: the melanoma trial clearly de-risked the business, but how much future oncology success is already embedded in the valuation?
Moderna Stock Gets a Wolfe Upgrade — But Not a Buy Rating
Wolfe Research moved Moderna from Underperform to Peer Perform, effectively removing its bearish stance rather than making an outright bullish call. The firm did not assign a new price target, but said the positive INTerpath-001 results create a “much clearer” regulatory pathway for Moderna and Merck to pursue approval of intismeran in adjuvant melanoma. Wolfe also argued that success in melanoma logically increases the probability that the personalized mRNA platform can work in other cancers now moving through late-stage development.
That distinction is important because the upgrade is both positive and cautious. Wolfe now estimates $9.2 billion of unadjusted peak sales across four indications before the economics are shared with Merck, but it is not telling investors that all of that value should immediately be capitalized into Moderna stock. The company and Merck share economics on the program, future indications still need to succeed clinically, and the full Phase 3 melanoma data have not yet been disclosed. In other words, Wolfe is acknowledging that Moderna’s fundamental story has improved dramatically while stopping short of saying the stock is obviously cheap after its explosive rally.
The Cancer Trial Changed the Moderna Investment Story
The catalyst was the Phase 3 INTerpath-001 study, which tested intismeran autogene together with Merck’s Keytruda in patients with completely resected Stage IIB-IV melanoma. The combination met its primary endpoint of recurrence-free survival and a key secondary endpoint of distant metastasis-free survival, producing statistically significant and clinically meaningful improvements compared with Keytruda alone. Moderna and Merck said the safety profile remained consistent with earlier experience and that they plan to discuss potential regulatory submissions with authorities.
Related articles
The result is significant because intismeran is not a conventional off-the-shelf vaccine. The therapy is created specifically for each patient by analyzing mutations in that person’s tumor and designing an individualized mRNA treatment intended to train the immune system to recognize those cancer-specific neoantigens. If regulators ultimately approve it, the product could become one of the first major commercial validations of personalized mRNA cancer therapy — potentially proving that the technology Moderna became famous for during COVID can create value far beyond infectious disease.
Earlier Data Explain Why Wall Street Is So Excited
The Phase 3 announcement did not disclose the exact hazard ratio, which is one reason analysts still want to see the detailed dataset. But investors already had encouraging evidence from the earlier Phase 2b KEYNOTE-942 study. At five years of follow-up, intismeran plus Keytruda reduced the risk of recurrence or death by 49%, with a hazard ratio of 0.51, and reduced the risk of distant metastasis or death by 59% compared with Keytruda alone.
Wolfe Research expects the Phase 3 recurrence-free-survival hazard ratio to land somewhere around 0.60 to 0.70, while warning that a result above roughly 0.75 might not be viewed as sufficiently compelling clinically. That makes the upcoming full-data presentation potentially just as important for Moderna stock as the topline announcement. The trial has technically succeeded, but Wall Street now wants to know by how much, how durable the benefit appears, whether overall-survival trends remain encouraging and whether any additional safety or manufacturing complexities emerge when the detailed results are presented.
$9.2 Billion in Peak Sales Explains the New Valuation Debate
Wolfe’s $9.2 billion estimate across four indications illustrates why MRNA shares reacted so violently. Moderna and Merck are studying intismeran across multiple tumors, including melanoma, non-small cell lung cancer, bladder cancer and renal cell carcinoma, with several Phase 2 and Phase 3 programs already underway. A successful platform across several major cancer markets would give Moderna something it has badly needed since the COVID boom faded: a large, durable revenue franchise capable of changing the company’s long-term earnings trajectory.
Yet investors need to distinguish total commercial sales from the value accruing to Moderna. Wolfe’s figure is unadjusted for clinical probability and comes before the economics are divided with Merck, while Reuters Breakingviews noted that the enormous market-cap increase following the Phase 3 announcement effectively assumes success extending well beyond melanoma alone. Barclays estimates melanoma itself could generate around $3 billion in annual sales by 2035, but because profits are shared and commercialization takes time, melanoma alone may struggle to justify the entire valuation increase already seen in Moderna and Merck. The market is therefore already wagering that intismeran becomes a platform, not merely a single-indication product.
Wall Street Is Repricing MRNA at Extraordinary Speed
Wolfe is not alone in changing its view. Bank of America upgraded Moderna from Underperform to Neutral and lifted its price target from $40 to $170, describing the melanoma success as a watershed event that improves Moderna’s ability to diversify away from infectious disease. William Blair upgraded the stock to Outperform and reportedly increased its estimated probability of melanoma approval to 90%, while Barclays raised its target dramatically to $125 from $48 but retained an Equal Weight rating.
The disagreement between analysts is revealing. Barclays argues that current levels already give intismeran substantial credit across multiple tumor types, while Wolfe’s shift only reaches Peer Perform and JPMorgan remained bearish after the rally. That means the market is no longer debating whether the Phase 3 result was important — virtually everyone agrees it was. The disagreement is over what probability investors should assign to successful expansion into other cancers and how much those future profits are worth today.
Moderna Still Has a Major Cash-Burn Problem
The oncology breakthrough does not erase Moderna’s near-term financial challenges. In the second quarter, the company generated only about $0.1 billion of revenue while reporting a $0.8 billion GAAP net loss, or $1.97 per share. Cash, cash equivalents and investments stood at $6.9 billion at June 30, down from $7.5 billion three months earlier, and Moderna subsequently paid $950 million in July related to a previously announced litigation settlement.
Management expects to finish 2026 with approximately $4.7 billion to $5.2 billion in cash, while targeting up to 10% revenue growth for the year and continuing to cut expenses. R&D spending is now expected at roughly $2.9 billion, slightly below the company’s previous outlook, while SG&A expenses are projected near $1 billion. The successful cancer trial makes that spending easier for investors to justify because there is now a credible late-stage asset capable of producing major revenue, but Moderna still needs to bridge the financial gap between today’s cash burn and a potential oncology launch.
A 2027 Melanoma Launch Could Change the Revenue Mix
Reuters reported that analysts see the possibility of a 2027 commercial launch in melanoma if the regulatory process proceeds favorably. Moderna and Merck have said they intend to engage regulators on filing submissions, although neither company has yet provided a definitive approval timetable. The overall-survival endpoint also continues to mature, and regulators will ultimately determine whether the available recurrence and metastasis data support approval.
If intismeran reaches the market, it would fundamentally alter Moderna’s revenue composition. The company is still highly associated with seasonal respiratory vaccines, a business characterized by substantial year-to-year demand uncertainty and heavy revenue concentration in the second half of the year. Oncology could provide a longer-duration growth engine with different pricing, treatment patterns and competitive dynamics, while successful personalized manufacturing would create technical barriers to entry that could strengthen Moderna’s position.
Manufacturing Could Become the Hidden Risk
Personalization is also one of the program’s biggest challenges. Each intismeran treatment must be designed around mutations identified in an individual patient’s tumor, meaning commercial success requires Moderna and Merck to reliably sequence tumor material, manufacture a unique therapy and deliver it rapidly enough to fit into clinical treatment schedules. The Wall Street Journal has reported that the process currently takes around six weeks, illustrating how different the production model is from manufacturing millions of identical vaccine doses.
That complexity could eventually become either a competitive moat or a commercial bottleneck. If Moderna demonstrates that its manufacturing platform can produce individualized therapies at scale with predictable turnaround times and attractive economics, few rivals may be able to replicate the infrastructure quickly. But manufacturing delays, high costs or reimbursement complications could limit adoption even if the clinical data remain excellent. This is why detailed regulatory and commercialization commentary will matter increasingly as the program moves beyond its clinical breakthrough.
Outlook: What Moderna Stock Investors Should Watch Next
For Moderna stock, the next major catalyst is the complete Phase 3 dataset. Wolfe expects detailed results could emerge around the ESMO 2026 meeting in Madrid in late October, although Moderna and Merck have only publicly said that results will be presented at an upcoming international medical meeting. Investors should focus on the recurrence-free-survival hazard ratio, distant-metastasis results, overall-survival trends, safety, manufacturing timelines and what regulators say about the path toward a potential filing.
Beyond melanoma, results from lung, bladder and kidney-cancer trials will determine whether Wolfe’s $9.2 billion opportunity begins to look realistic or overly optimistic. The successful Phase 3 trial has unquestionably made Moderna a stronger company than it appeared to be only weeks ago, and it significantly reduces the risk that the company’s mRNA platform remains dependent on respiratory vaccines. But after a 177% one-day rally, investors are now paying for at least some of that future success upfront.
Moderna has finally delivered the oncology breakthrough Wall Street spent years waiting for. The next test for MRNA stock is harder: proving that one melanoma victory can become a multibillion-dollar cancer franchise.
